Shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) advanced 2.4% after the company announced that the U.S. Food and Drug Administration has approved its Investigational New Drug (IND) application for ...

First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...

RCKT Developing Another Gene-Therapy for Heart Diseases Besides RP-A601, RCKT is developing another AAV-based gene therapy candidate, RP-A701, for treating BAG3-associated dilated cardiomyopathy (BAG3 ...

Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), ...

Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to a well-tolerated safety profile, which has been heralded by analysts as ...

Showcased 7 presentations at ISSCR 2025, including a featured oral presentation on first-in-human gene therapy for heart failure, powered by their proprietary human mini-Heart technology. FDA-backed ...

Novo Nordisk may be breaking Heartseed's heart. As part of a company-wide restructuring under new CEO Maziar Mike Doustdar, the big pharma has axed a cell therapy collaboration with Heartseed worth ...

Biomedical engineer Nenad Bursac, standing, and postdoctoral associate Tianyu Wu image a heart tissue patch through a microscope at the Bursac lab at the Duke University Pratt School of Engineering.

Sarepta will stop shipping its Duchenne muscular dystrophy gene therapy Elevidys following ongoing discussions with the FDA over safety labeling. The drugmaker said the pause, effective July 22, will ...